1. Immunization with PfGBP130 generates antibodies that inhibit RBC invasion by P. falciparum parasites.
- Author
-
Johnson Y, Shakri AR, Pond-Tor S, Jnawali A, Najrana T, Wu H, Badhai J, Alameh MG, Weissman D, Kabyemela E, Duffy P, Fried M, Kurtis J, and Raj DK
- Subjects
- Animals, Female, Humans, Mice, Antigens, Protozoan immunology, Immunization, Antibodies, Protozoan immunology, Erythrocytes parasitology, Erythrocytes immunology, Malaria Vaccines immunology, Malaria, Falciparum immunology, Malaria, Falciparum prevention & control, Plasmodium falciparum immunology, Protozoan Proteins immunology, Protozoan Proteins genetics
- Abstract
Background: Despite decades of effort, Plasmodium falciparum malaria remains a leading killer of children. The absence of a highly effective vaccine and the emergence of parasites resistant to both diagnosis as well as treatment hamper effective public health interventions., Methods and Results: To discover new vaccine candidates, we used our whole proteome differential screening method and identified PfGBP130 as a parasite protein uniquely recognized by antibodies from children who had developed resistance to P. falciparum infection but not from those who remained susceptible. We formulated PfGBP130 as lipid encapsulated mRNA, DNA plasmid, and recombinant protein-based immunogens and evaluated the efficacy of murine polyclonal anti-PfGBP130 antisera to inhibit parasite growth in vitro. Immunization of mice with PfGBP130-A (aa 111-374), the region identified in our differential screen, formulated as a DNA plasmid or lipid encapsulated mRNA, but not as a recombinant protein, induced antibodies that inhibited RBC invasion in vitro . mRNA encoding the full ectodomain of PfGBP130 (aa 89-824) also generated parasite growth-inhibitory antibodies., Conclusion: We are currently advancing PfGBP130-A formulated as a lipid-encapsulated mRNA for efficacy evaluation in non-human primates., Competing Interests: Author JK is a scientific co-founder of Ocean Biomedical which seeks to develop malaria vaccines. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Johnson, Shakri, Pond-Tor, Jnawali, Najrana, Wu, Badhai, Alameh, Weissman, Kabyemela, Duffy, Fried, Kurtis and Raj.)
- Published
- 2024
- Full Text
- View/download PDF